5-bromonicotinic acid profile

5-Bromonicotinic acid is a nicotinic acid derivative with a bromine atom at the 5-position. It is a white solid and is used as a building block in organic synthesis, particularly for the preparation of pharmaceuticals and agrochemicals. The compound can be synthesized via various methods, including the bromination of nicotinic acid or by using a variety of other starting materials. 5-Bromonicotinic acid has shown various pharmacological effects, including anti-inflammatory, antibacterial, and anti-tumor activities. It is studied because of its potential applications in the development of new drugs and other bioactive molecules.'

5-bromonicotinic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	88707
CHEMBL ID	247336
SCHEMBL ID	112388
MeSH ID	M0255994

Synonym
AC-1735
5-bromo nicotinic acid
BB 0246832
5-bromo-nicotinic acid
5-bromo-pyridine-3-carboxylic acid
nsc 9461
nicotinic acid, 5-bromo-
5-bromo-3-pyridinecarboxylic acid ,
brn 0115854
einecs 244-065-5
20826-04-4
nsc9461
mls000737908 ,
nsc-9461
IDI1_017418
3-pyridinecarboxylic acid, 5-bromo-
5-bromonicotinic acid
inchi=1/c6h4brno2/c7-5-1-4(6(9)10)2-8-3-5/h1-3h,(h,9,10
5-bromopyridine-3-carboxylic acid, 98%
smr000528085
MAYBRIDGE3_006031
HMS1448C03
B1818
CHEMBL247336 ,
F3095-3197
bdbm50216531
5-bromopyridine-3-carboxylic acid
AKOS000119560
STK711127
HMS2884O04
5-22-02-00181 (beilstein handbook reference)
zdb972tsh7 ,
ec 244-065-5
unii-zdb972tsh7
AM20050934
FT-0620167
SCHEMBL112388
FS-1199
mfcd00009783
SY001554
3-bromo-5-pyridine-carboxylic acid
W-107593
CS-W020058
3-bromo-5-pyridine carboxylic acid
DTXSID70174944
CCG-245109
nicergoline impurity d, european pharmacopoeia (ep) reference standard
3-bromo-5-pyridinecarboxylic acid
BCP27322
Q63392865
5-bromonicotinicacid
EN300-20046
SB10611
Y31 ,
AB6459
HY-Y1013
Z104476582

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	0.0067	0.0032	45.4673	12,589.2998	AID2517
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	89.1251	0.0355	20.9770	89.1251	AID504332
DNA polymerase beta	Homo sapiens (human)	Potency	100.0000	0.0224	21.0102	89.1251	AID485314
eyes absent homolog 2 isoform a	Homo sapiens (human)	Potency	100.0000	1.1998	14.6419	50.1187	AID488837
Glycoprotein hormones alpha chain	Homo sapiens (human)	Potency	5.0119	4.4668	8.3448	10.0000	AID624291
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	19.9526	1.9953	25.5327	50.1187	AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
D-aspartate oxidase	Homo sapiens (human)	IC50 (µMol)	10,000.0000	0.0040	0.3937	0.8550	AID1247843
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Hydroxycarboxylic acid receptor 2	Homo sapiens (human)	EC50 (µMol)	13.6000	0.0087	1.2017	6.3096	AID308653
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G protein-coupled receptor signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Glycoprotein hormones alpha chain	Homo sapiens (human)
hormone-mediated signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
regulation of signaling receptor activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of steroid biosynthetic process	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell migration	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid gland development	Glycoprotein hormones alpha chain	Homo sapiens (human)
luteinizing hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid hormone generation	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
neutrophil apoptotic process	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
negative regulation of lipid catabolic process	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
positive regulation of adiponectin secretion	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
insemination	D-aspartate oxidase	Homo sapiens (human)
grooming behavior	D-aspartate oxidase	Homo sapiens (human)
regulation of cell communication	D-aspartate oxidase	Homo sapiens (human)
D-amino acid catabolic process	D-aspartate oxidase	Homo sapiens (human)
hormone metabolic process	D-aspartate oxidase	Homo sapiens (human)
nervous system process	D-aspartate oxidase	Homo sapiens (human)
aspartate catabolic process	D-aspartate oxidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protein binding	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
nicotinic acid receptor activity	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
protein binding	D-aspartate oxidase	Homo sapiens (human)
D-aspartate oxidase activity	D-aspartate oxidase	Homo sapiens (human)
D-glutamate oxidase activity	D-aspartate oxidase	Homo sapiens (human)
FAD binding	D-aspartate oxidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
Golgi lumen	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
pituitary gonadotropin complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
plasma membrane	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
cell junction	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
plasma membrane	Hydroxycarboxylic acid receptor 2	Homo sapiens (human)
peroxisome	D-aspartate oxidase	Homo sapiens (human)
peroxisome	D-aspartate oxidase	Homo sapiens (human)
peroxisomal matrix	D-aspartate oxidase	Homo sapiens (human)
cytosol	D-aspartate oxidase	Homo sapiens (human)
cytoplasm	D-aspartate oxidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1422526	Inhibition of beta hematin formation after 5 to 6 hrs by NP40 detergent-based assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.
AID1422527	Antiplasmodial activity against asexual erythrocyte stage of chloroquine-sensitive Plasmodium falciparum NF54 infected in human red blood cells after 48 hrs by lactate dehydrogenase assay	2018	European journal of medicinal chemistry, Nov-05, Volume: 159	Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.
AID1247844	Inhibition of human recombinant DAO expressed in Escherichia coli BL21(DE3) using D-Asp and D-Ala assessed as 2-oxo acid production after 10 mins by colorimetric assay	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1247843	Inhibition of human recombinant DDO expressed in Escherichia coli BL21(DE3) using D-Asp and D-Ala assessed as 2-oxo acid production after 10 mins by colorimetric assay	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID308653	Agonist activity at human cloned GPR109a receptor by forskolin-stimulated cAMP production test	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Agonist lead identification for the high affinity niacin receptor GPR109a.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (9.09)	18.2507
2000's	3 (27.27)	29.6817
2010's	6 (54.55)	24.3611
2020's	1 (9.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
benzoic acid Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.	2.11	1	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
malonic acid malonic acid : An alpha,omega-dicarboxylic acid in which the two carboxy groups are separated by a single methylene group.. dicarboxylic acid : Any carboxylic acid containing two carboxy groups.	2.11	1	alpha,omega-dicarboxylic acid	human metabolite
acetanilide acetanilide: a phenylacetamide; use ACETANILIDES for the plural group meaning of the singular term. N-phenylacetamide : A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a phenyl group.	2.17	1	acetamides; anilide	analgesic
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	2.47	2	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
pyrazinoic acid pyrazinoic acid: active metabolite of pyrazinamide; structure. pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide.	2.03	1	pyrazinecarboxylic acid	antitubercular agent; drug metabolite
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.17	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
benzimidazole 1H-benzimidazole : The 1H-tautomer of benzimidazole.	2.17	1	benzimidazole; polycyclic heteroarene
3-aminobenzoic acid 3-aminobenzoic acid: RN given refers to parent cpd. 3-aminobenzoic acid : An aminobenzoic acid carrying an amino group at position 3.	2.11	1	aminobenzoic acid
5-chlorosalicylic acid 5-chlorosalicylic acid: major metabolite of meseclazone; RN given refers to parent cpd. 5-chlorosalicylic acid : A monohydroxybenzoic acid that is 2-hydroxybenzoic acid (salicylic acid) in which the hydrogen at position 5 is replaced by chlorine.	2.11	1	chlorobenzoic acid; monochlorobenzenes; monohydroxybenzoic acid
5-methylpyrazole-3-carboxylic acid 5-methylpyrazole-3-carboxylic acid: structure. 5-methyl-pyrazole-3-carboxylic acid : A memebr of the class of pyrazoles that is 1H-pyrazole with methyl and carboxylic acid group substituents at positions 5 and 3 respectively.	2.03	1	monocarboxylic acid; pyrazoles	metabolite
3-aminopyridine [no description available]	2.11	1
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.17	1	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
3,5-pyridinedicarboxylic acid 3,5-pyridinedicarboxylic acid: structure in first source	2.11	1	pyridinedicarboxylic acid
3-hydroxypicolinic acid [no description available]	2.11	1	monocarboxylic acid; monohydroxypyridine	MALDI matrix material
6-aminonicotinic acid 6-aminonicotinic acid: RN given refers to parent cpd. 6-aminonicotinic acid : An aminonicotinic acid in which the amino group is situated at position 6 of the pyridine ring.	2.11	1	aminonicotinic acid; aminopyridine; aromatic amine	metabolite
5-hydroxynicotinic acid [no description available]	2.11	1	aromatic carboxylic acid; pyridines
nicergoline Nicergoline: An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It may ameliorate cognitive deficits in CEREBROVASCULAR DISORDERS.	6.98	1	organic heterotetracyclic compound; organonitrogen heterocyclic compound
5-fluorosalicylic acid 5-fluorosalicylic acid: structure given in first source; product from action of alkaline phosphatase on 5-fluorosalicyl phosphate; forms highly fluorescent terbium ternary complex	2.11	1
2-aminonicotinic acid 2-aminonicotinic acid: structure in first source. 2-aminonicotinic acid : An aminonicotinic acid in which the amino group is situated at position 2 of the pyridine ring.. aminonicotinic acid : An aromatic amino acid that is nicotinic acid in which one of the hydrogens attached to the pyridine ring is replaced by an amino group. A 'closed class'.	2.11	1	aminonicotinic acid; aminopyridine	metabolite
3-aminopicolinic acid [no description available]	2.11	1
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.01	1	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
5-fluoro-3-pyridinecarboxylic acid [no description available]	2.47	2
3-phenyl-1H-pyrazole-5-carboxylic acid [no description available]	2.03	1	pyrazoles; ring assembly
5-aminonicotinic acid 5-aminonicotinic acid: an inhibitor of D-aspartate oxidase; structure in first source. 5-aminonicotinic acid : An aminonicotinic acid in which the amino group is situated at position 5 of the pyridine ring.	2.11	1	aminonicotinic acid; aminopyridine; aromatic amine	metabolite
3-methyl-5-isoxazolecarboxylic acid 3-methyl-5-isoxazolecarboxylic acid: N1 same as NM; RN given refers to parent cpd	2.03	1
rubidium Rubidium: An element that is an alkali metal. It has an atomic symbol Rb, atomic number 37, and atomic weight 85.47. It is used as a chemical reagent and in the manufacture of photoelectric cells.	2.01	1	alkali metal atom

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Plasmodium falciparum Malaria [description not available]	2.17	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.17	1

5-bromonicotinic acid

Description

Cross-References

Synonyms (57)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (29)

Molecular Functions (9)

Ceullar Components (11)

Bioassays (19)

Research

Studies (11)

Market Indicators

Research Demand Index: 24.21

Study Types

5-bromonicotinic acid

Description

Cross-References

Synonyms (57)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (29)

Molecular Functions (9)

Ceullar Components (11)

Bioassays (19)

Research

Studies (11)

Market Indicators

Research Demand Index: 24.21

Study Types

Related Drugs (26)

Related Conditions (6)